1. Inicio
  2. Publicaciones
  3. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.

Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.

Fecha de publicación:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Wolff D
  • Cutler C
  • Lee SJ
  • Pusic I
  • Bittencourt H
  • White J
  • Hamadani M
  • Arai S
  • Salhotra A
  • Perez-Simon JA
  • Alousi A
  • Choe H
  • Kwon M
  • Kim I
  • Socié G
  • Chhabra S
  • Radojcic V
  • O'Toole T
  • Tian C
  • Ordentlich P
  • DeFilipp Z
  • Kitko CL
  • AGAVE-201 Investigators

Unidades

Abstract

BACKGROUND: Colony-stimulating factor 1 receptor (CSF1R)-dependent monocytes and macrophages are key mediators of chronic graft-versus-host disease (GVHD), a major long-term complication of allogeneic hematopoietic stem-cell transplantation. The CSF1R-blocking antibody axatilimab has shown promising clinical activity in chronic GVHD. METHODS: In this phase 2, multinational, pivotal, randomized study, we evaluated axatilimab at three different doses in patients with recurrent or refractory chronic GVHD. Patients were randomly assigned to receive axatilimab, administered intravenously, at a dose of 0.3 mg per kilogram of body weight every 2 weeks (0.3-mg dose group), at a dose of 1 mg per kilogram every 2 weeks (1-mg dose group), or at a dose of 3 mg per kilogram every 4 weeks (3-mg dose group). The primary end point was overall response (complete or partial response) in the first six cycles; the key secondary end point was a patient-reported decrease in chronic GVHD symptom burden, as assessed by a reduction of more than 5 points on the modified Lee Symptom Scale (range, 0 to 100, with higher scores indicating worse symptoms). The primary end point would be met if the lower bound of the 95% confidence interval exceeded 30%. RESULTS: A total of 241 patients were enrolled (80 patients in the 0.3-mg dose group, 81 in the 1-mg dose group, and 80 in the 3-mg dose group). The primary end point was met in all the groups; an overall response was observed in 74% (95% confidence interval [CI], 63 to 83) of the patients in the 0.3-mg dose group, 67% (95% CI, 55 to 77) of the patients in the 1-mg dose group, and 50% (95% CI, 39 to 61) of the patients in the 3-mg dose group. A reduction of more than 5 points on the modified Lee Symptom Scale was reported in 60%, 69%, and 41% of the patients in the three dose groups, respectively. The most common adverse events were dose-dependent transient laboratory abnormalities related to CSF1R blockade. Adverse events leading to discontinuation of axatilimab occurred in 6% of the patients in the 0.3-mg dose group, 22% in the 1-mg dose group, and 18% in the 3-mg dose group. CONCLUSIONS: Targeting CSF1R-dependent monocytes and macrophages with axatilimab resulted in a high incidence of response among patients with recurrent or refractory chronic GVHD. (Funded by Syndax Pharmaceuticals and Incyte; AGAVE-201 ClinicalTrials.gov number, NCT04710576.).

Copyright © 2024 Massachusetts Medical Society.

Datos de la publicación

ISSN/ISSNe:
0028-4793, 1533-4406

NEW ENGLAND JOURNAL OF MEDICINE  MASSACHUSETTS MEDICAL SOC

Tipo:
Article
Páginas:
1002-1014
PubMed:
39292927

Citas Recibidas en Web of Science: 38

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Compartir